10
May

08:00 AM PDT

Oncology

Name: Oncology Conferences 2023
Start: 2023-05-10T08:00
End: 2023-05-10T16:50
Location: Hard Rock Hotel San Diego

Strategy Meeting West Coast USA 2023

Exploring Promising Areas in Oncology Research Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

Hard Rock Hotel San Diego

Strategy Meetings

Transforming the way we network

Often at conferences, seminars and summits you are placed amongst a large pool of industry professionals, however the opportunity to share personal insights and knowledge is limited. With Proventa International?s unique format of executive roundtables, you are placed side by side with those same industry leaders, in private, facilitated discussions on pre-selected topics.rn

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Oncology Strategy Meeting.

Ana Krtolica

Senior Vice President, Preclinical Development Oryn Therapeutics

Anna Vardanyan

Vice President, Business Development Inmagene Biopharma

Oscar Segurado

Chief Medical Officer ASC Therapeutics

Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.

Boris Minev

President, Medical & Scientific Affairs Calidi Biotherapeutics

Charles Theuer

President & CEO TRACON Pharmaceuticals

Dr. Theuer has served as President, Chief Executive Officer and a member of the board of directors of TRACON Pharmaceuticals since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997.  Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.

Gajanan Bhat

Senior Vice President, Development Team Lead TORL Biotherapeutics, LLC

Gregory Opiteck

Vice President Head of Translational Sciences Allogene Therapeutics

An early adopter & advocate of precision medicine-driven clinical development, Greg has led mechanism‑based translational strategies that link drug design, human biology, and clinical data to inform decision-making in early development programs for over 25 years. He currently serves as Vice President, Head of Translational Medicine, at Janux Therapeutics here in San Diego, CA, where he oversees hypothesis‑driven translational and biomarker approaches supporting the clinical development of tumor‑activated T‑cell engager therapeutics. His work focuses on integrating pharmacology, immune activation, and on‑tumor biology to drive therapeutic activity & safety by explaining variance to treatment in indications such as metastatic castration‑resistant prostate cancer (mCRPC), including the lead JANX007 TCE program. 
Prior to joining Janux, Greg was Vice President and Head of Precision and Translational Medicine at Affini-T Therapeutics and previously held roles of increasing responsibility in early clinical development at Receptos, Merck, and Bristol Myers Squibb. Greg earned his PhD from the University of North Carolina, Chapel Hill, and his BSc from the University of Notre Dame.

Jack Florio

Managing Director Weild & Co

Jason B. Litten

Chief Medical Offficer Chimeric Therapeutics

Joanne Sloan Lancaster

Vice President, Program Team Leadership NGM Bio

Joe Stalder

Executive Director Project Management Mirati Therapeutics

Karin Zeh

Vice President, Program and Alliance Management Genesis Therapeutics

Majid Ghoddusi

Executive Director, Clinical Biomarker Poseida Therapeutics

Matthew Spear

Chief Development Officer / Chief Medical Officer Denovo Biopharma

Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications.
CAR-T cell, RMAT, Gene Therapy, Gene Editing, AAV, HSV, transposon, hemophilia, Oncology, Hematology, NHL, myeloma, AML, MDS, prostate cancer, lung cancer, breast cancer, pancreatic cancer, GBM, H&N cancer, sarcoma, ovarian cancer, Oncolytic, Epigenetic, Biomarkers, Companion Diagnostics. Small Molecules, California Institute for Regenerative Medicine (CIRM), Immunotherapy, Vaccine, Antibody, Phage Display, sickle-cell, thalassemia, MPS I&II, MEK, PARP, CDK, VEGFR, Angiogenesis, VDA, HDAC, Proteosome, PI3K, BRD, JAK, PIM, FGFR, WT1, lysine-specific demethylase, OTC

Hui Zou

Chief Scientific Officer (CSO) Phanes Therapeutics

Nathaniel Wang

Chief Executive Officer and Co-Founder Replicate Biosciences

Ron Shazer

Vice President of Cllnical Development Mirati Therapeutics

Stan Jin

Co-founder and Chief Executive Officer Molecular Axiom

Will Robberts

President LIPAC Oncology

First name	Last name	Job title	Company name	Photo URL	Bio Position
Ana	Krtolica	Senior Vice President, Preclinical Development	Oryn Therapeutics	https://proventainternational.com/wp-content/uploads/2022/01/anakrtolica.jpg	Ana completed PhD at University of Rochester. As a postdoc and then, scientist at LBNL and UCSF she explored the influence of microenvironment on carcinogenesis and stem cell phenotype. Ana co-founded and led StemLifeLine, a startup focusing on cell therapy and development of the cancer drug discovery platform. After joining Omniox, Ana developed programs in oncology, ischemic stroke and critical care bringing its technology from early discovery to clinic. She currently leads translational and new indication efforts at Retrotope. Ana received >$5M in grants and serves on NIH Review Boards. She authored multiple patent applications and published >30 research papers.
Anna	Vardanyan	Vice President, Business Development	Inmagene Biopharma	https://proventainternational.com/wp-content/uploads/2023/01/Anna-Vardanyan.jpg	Physician-Scientist, Dr. Anna Vardanyan has built a career founded on passion for life science innovation and development of new therapies for patients in need. She currently holds the position of Vice President, Business Development at Inmagene Therapeutics after her stint as Executive Director of Business Development at Turning Point/BMS. Dr. Vardanyan has 15+ years of pharma and biotech experience and held various positions of increasing responsibility in R&D and Business Development at Genzyme, Sanofi, Everest Medicines, Turning Point Therapeutics and BMS. She has extensive experience managing cross border transactions, including US, EU, and Asia, overseeing the full lifecycle of BD opportunities, and proven record of leadership spanning a broad range of therapeutic areas.
Oscar	Segurado	Chief Medical Officer	ASC Therapeutics	https://proventainternational.com/wp-content/uploads/2021/09/Photo_Oscar-Segurado_F0-e1631533577811.jpeg	Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.
Boris	Minev	President, Medical & Scientific Affairs	Calidi Biotherapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Boris-Minev.jpg	Dr. Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development. Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing translational projects on oncolytic virotherapy, immunotherapy and nanotechnology. Dr. Minev is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.
Charles	Theuer	President & CEO	TRACON Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/01/Charles-Theuer-Photo-e1618412949352.jpg	Dr. Theuer has served as President, Chief Executive Officer and a member of the board of directors of TRACON Pharmaceuticals since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
Gajanan	Bhat	Senior Vice President, Development Team Lead	TORL Biotherapeutics, LLC	https://proventainternational.com/wp-content/uploads/2021/04/Gajanan-Bhat.jpg
Gregory	Opiteck	Vice President Head of Translational Sciences	Allogene Therapeutics	https://proventainternational.com/wp-content/uploads/2023/05/Gregory-Opiteck.jpg	An early adopter & advocate of precision medicine-driven clinical development, Greg has led mechanism‑based translational strategies that link drug design, human biology, and clinical data to inform decision-making in early development programs for over 25 years. He currently serves as Vice President, Head of Translational Medicine, at Janux Therapeutics here in San Diego, CA, where he oversees hypothesis‑driven translational and biomarker approaches supporting the clinical development of tumor‑activated T‑cell engager therapeutics. His work focuses on integrating pharmacology, immune activation, and on‑tumor biology to drive therapeutic activity & safety by explaining variance to treatment in indications such as metastatic castration‑resistant prostate cancer (mCRPC), including the lead JANX007 TCE program. Prior to joining Janux, Greg was Vice President and Head of Precision and Translational Medicine at Affini-T Therapeutics and previously held roles of increasing responsibility in early clinical development at Receptos, Merck, and Bristol Myers Squibb. Greg earned his PhD from the University of North Carolina, Chapel Hill, and his BSc from the University of Notre Dame.
Jack	Florio	Managing Director	Weild & Co	https://proventainternational.com/wp-content/uploads/2023/03/Jack-Florio.jpg	Jack Florio is a life sciences executive with 50 years of experience across the full range of pharma / biotech companies spanning early-stage company formation through capital formation, operations, and exits. This gives him a unique view of strategy and tactics across the life cycle of many companies. Jack is a Managing Director with Weild & Co. where he works on advisory, capital formation and M&A deals across the sector. He is also an angel investor with NuFund Venture Group and a Partner with Deallus, a global life sciences consultancy. Jack has held operational roles in both small and large companies across the life science space in the US and Europe including a 30 year career with Eli Lilly and Company. Jack has a BS in Pharmaceutical Sciences from Columbia University and an MBA from NYU/Stern School of Business.
Jason	B. Litten	Chief Medical Offficer	Chimeric Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Jason-B-Litten.jpg	Jason B. Litten MD is the Chief Medical Officer at Chimeric Therapeutics and an expert in cellular therapeutics and clinical oncology. Prior to Chimeric, Jason served as the Chief Medical Officer at Artiva Biotherapeutics. Jason holds a BS from Cornell University and MD from Emory University. He completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern. Since leaving academic medicine over 15 years ago, Dr Litten has been dedicated to developing new medicines for cancer patients in the biotech and pharmaceutical field.
Joanne	Sloan Lancaster	Vice President, Program Team Leadership	NGM Bio	https://proventainternational.com/wp-content/uploads/2023/01/Joanne-Sloan.jpg	Dr. Sloan Lancaster brings over 25 years of drug development experience, focusing on autoimmune and immune oncology early clinical development. She is currently VP Program Team Leadership, Oncology Clinical Development, at NGM. Joanne began her career at Eli Lilly in several roles of increasing leadership, including Therapeutic Antibody Discovery, early clinical development within Chorus Lilly, and Head of Exploratory Medicine and Clinical Pharmacology, Immunology and Oncology. Joanne was most recently Vice President, Program Team Leadership at Calico prior to joining NGM. Joanne received her BSc in Immunology from the University of Glasgow, her PhD in Immunology from Washington University St. Louis, and post-doctoral training at the NIH.
Joe	Stalder	Executive Director Project Management	Mirati Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Joe-Stalder.jpg	Joe Stalder is an Executive Director of Project Management at Mirati Therapeutics in San Diego, CA, co-founder of Groundswell Pharma Consulting, and editor of the book “Project Management for Drug Developers”. Joe has over 10 years of project management experience in pharmaceutical development in large and small companies. His experience includes Project Management department head, PMO head, and Lead Project Manager on several early- and late-stage development assets in oncology, infectious disease, cardiology, metabolism, and pulmonology. Joe is also a regular speaker at biopharma PPM conferences and is involved in biopharma PPM community organizations including PIPMG and BiopharmaPM.
Karin	Zeh	Vice President, Program and Alliance Management	Genesis Therapeutics	https://proventainternational.com/wp-content/uploads/2023/02/Karen-Zeh.jpg	Dr. Karin Zeh has 25 years of R&D leadership experience focusing on rare diseases and unmet need indications. Most recently Dr. Zeh was employed at Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb) as VP of Program and Portfolio Management and served as Program Team Lead for multiple programs. Dr. Zeh began her career in industry as a research scientist but since gained extensive expertise in building and leading program teams and the program management function working with innovative biotechnology companies at all stages of development. Dr. Zeh received her PhD from the University of Heidelberg, Germany and conducted post-graduate work at the Sanford-Prebys Burnham Institute in La Jolla, California.
Majid	Ghoddusi	Executive Director, Clinical Biomarker	Poseida Therapeutics	https://proventainternational.com/wp-content/uploads/2021/01/Majid-Ghoddusi_Posida-Therapeutics-e1618412913763.jpg	Dr. Ghoddusi has over 15 years of experience in some of the most challenging areas of oncology with focus on biomarkers in clinical development. Dr Ghoddusi has broad and overarching insights into unmet therapeutic areas with expertise in translational sciences and clinical biomarker development which allows him to provide unique perspective on how to propel therapeutic projects from discovery to approval. Trained as a translational pathologist he has held impactful positions at large pharmaceutical and small biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, Poseida Therapeutics. His current role at Janux Therapeutics as Executive Director is to plan and execute wholesome clinical biomarkers strategy in support of Janux T-cell engagers pipeline.
Matthew	Spear	Chief Development Officer / Chief Medical Officer	Denovo Biopharma	https://proventainternational.com/wp-content/uploads/2023/01/Matthew-Spear.jpg	Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications. CAR-T cell, RMAT, Gene Therapy, Gene Editing, AAV, HSV, transposon, hemophilia, Oncology, Hematology, NHL, myeloma, AML, MDS, prostate cancer, lung cancer, breast cancer, pancreatic cancer, GBM, H&N cancer, sarcoma, ovarian cancer, Oncolytic, Epigenetic, Biomarkers, Companion Diagnostics. Small Molecules, California Institute for Regenerative Medicine (CIRM), Immunotherapy, Vaccine, Antibody, Phage Display, sickle-cell, thalassemia, MPS I&II, MEK, PARP, CDK, VEGFR, Angiogenesis, VDA, HDAC, Proteosome, PI3K, BRD, JAK, PIM, FGFR, WT1, lysine-specific demethylase, OTC
Hui	Zou	Chief Scientific Officer (CSO)	Phanes Therapeutics	https://proventainternational.com/wp-content/uploads/2023/05/Ali-Vozza-Recovered-copy.jpg	Dr. Hui Zou is the Chief Scientific Officer (CSO) of Phanes Therapeutics. He is an experienced and accomplished oncologist in both academia of biological research and industry of drug development. Before joining the industry, Hui was a tenured Associate Professor at UT Southwestern Medical Center. He joined the industry to translate his scientific expertise into biomedical drug discovery and development. Before joining Phanes, he was the CSO of Gan&Lee Pharmaceuticals. Dr. Zou holds a PhD degree of genetics and development from Columbia University. He was awarded fellow of Jane Coffin Childs Memorial Fund for Medical Research, American Cancer Society Research Scholar, and Kenneth G. and Elaine A. Langone Scholar of Damon Runyon Cancer Research Foundation.
Nathaniel	Wang	Chief Executive Officer and Co-Founder	Replicate Biosciences	https://proventainternational.com/wp-content/uploads/2023/01/Nathaniel-Wang.jpg	Dr. Nathaniel Wang is the Chief Executive Officer and Cofounder at Replicate Bioscience. He has 15+ years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery and is also a recognized expert in the fields of immuno-oncology and infectious disease. Prior to Replicate Dr. Wang headed RNA Medicines business unit at Synthetic Genomics, which was acquired by Janssen in 2019. At Janssen, he led teams developing srRNA compounds in multiple therapeutic areas. He received a Ph.D. in Immunology from The Scripps Research Institute and a B.A. in Immunology from UC Berkeley.
Ron	Shazer	Vice President of Cllnical Development	Mirati Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Ron-Shazer.jpg	Ronald Shazer is Vice President, Clinical Development at Mirati Therapeutics in San Diego, CA. Ron has over 20 years of drug development experience which includes overseeing all development at a start-up to leading projects at large pharmaceutical companies. He has led the development of small molecule targeted therapies, antibody drug conjugates, bi-specific antibodies, and immunotherapies ranging from pre-IND to NDA. Ron’s clinical research experience began as an investigator on clinical studies at Cedars-Sinai Prostate Cancer Center. Since moving to industry, initially at Exelixis, Ron has held roles with increasing responsibility at Bristol-Myers Squib and Pfizer and has served as the Chief Medical Officer at Denovo Biopharma, Inspyr Therapeutics, and Tracon Pharmaceuticals.
Stan	Jin	Co-founder and Chief Executive Officer	Molecular Axiom	https://proventainternational.com/wp-content/uploads/2023/03/Stan-Jin.jpg	Stan is a scientist-turned-serial entrepreneur. Currently he is co-founder and CEO of Molecular Axiom, a cutting edge RNA based therapeutics company. Prior to that, he co-founded Fronthera Pharmaceuticals in 2015, which was acquired by Foresite Capital for $180M in March, 2021. A seasoned drug hunter, Stan has filed >60 patent applications and contributed to the discovery of a number of clinical programs in his 20 years of pharma/biotech industry experience. Stan earned his Ph.D. in synthetic organic chemistry from Texas A&M University, and was a postdoc fellow at University of Notre Dame.
Will	Robberts	President	LIPAC Oncology	https://proventainternational.com/wp-content/uploads/2023/02/Will-Robberts.jpg	Will is the President and Chief Financial Officer of LIPAC Oncology and TesoRx Pharma and a Board member of Enable Biosciences and Metanoia Bio. He has more than 20 years of experience in finance and operational excellence in healthcare, software, and technology companies. His diverse deal experience includes multiple unique licensing transactions, partnering deals and creative early stage investment rounds with a focus on limiting dilution for life science founders and their investors. Will is a KPMG Corporate Finance alumni and earned bachelor, honors and masters degrees from the University of Johannesburg, South Africa.

Ana Krtolica, Anna Vardanyan, Oscar Segurado, Boris Minev, Charles Theuer, Gajanan Bhat, Gregory Opiteck, Jack Florio, Jason B. Litten, Joanne Sloan Lancaster, Joe Stalder, Karin Zeh, Majid Ghoddusi, Matthew Spear, Hui Zou, Nathaniel Wang, Ron Shazer, Stan Jin, Will Robberts

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.

Senior Decision Makers

All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.

Private and Intimate Networking

Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.

Agenda

See Which Topics Are Up For Discussion

09:00

Roundtable Tracks

Immuno-Oncology Reprogramming The Tumor Microenvironment(TME) To Improve Immunotherapy Outcomes -Boris Minev President, Medical & Scientific Affairs, Calidi Biotherapeutics Targeted Therapy Improving Cancer Combination Therapy By Timing Drug Administration -Oscar Segurado Chief Medical Officer, ASC Therapeutics Precision Medicine/ Companion Diagnostics Beyond Genomics What Is The Potential And What Are Barriers To Multi Omics Profiling -Ana Krtolica Senior Vice President, Preclinical Development, Oryn Therapeutics Biomarker Discovery Employing the circulations of tumor DNA (ctDNA) as a biomarker or an early endpoint in early-stage solid tumor clinical trials -Majid Ghoddusi Executive Director, Clinical Biomarkers, Janux Therapeutics Clinical Research & Development Incorporating real-world-evidence in the clinical development process for faster submissions and accelerated approvals -Gajanan Bhat Senior Vice President, Clinical Sciences, Spectrum Pharmaceuticals (New) Investment, Private Equity & Venture Capital Partnerships Creative Solutions For Funding Early Stage Oncology Innovation -Will Robberts President, LIPAC Oncology

11:10

Roundtable Tracks

Immuno-Oncology Latest Innovations In Immunooncology To Unleash Better And More Effective Immunotherapy Options -Nathaniel Wang Chief Executive Officer and Co-Founder, Replicate Biosciences Targeted Therapy Addressing Operational Challenges Of Developing Targeted Therapies To Treat Increasingly Precise Oncologic Mutations -Joe Stalder Executive Director Project Management, Mirati Therapeutics -Ron Shazer Vice President of Cllnical Development, Mirati Therapeutics Precision Medicine/ Companion Diagnostics Biomarker Discovery Examining How Integrated Approaches To Cancer Biomarker Discovery May Reveal How Predictive Gene Signatures Are Of Cancer Progression Clinical Research & Development Evaluating The Benefits Of In House Clinical Development And Operations -Charles Theuer Chief Executive Officer, TRACON Pharmaceuticals Investment, Private Equity & Venture Capital Partnerships Best Practices And Success Factors To Raising Funds And Building An Innovative Biotech Company Which Assets And Technologies Investors Will Be Looking For In Your Intellectual Property Portfolio -Anna Vardanyan Vice President, Business Development, Inmagene Biopharma

13:40

Roundtable Tracks

Immuno-Oncology Advancing Cell Therapies For Solid Tumor Patients -Jason B. Litten Chief Medical Offficer, Chimeric Therapeutics Targeted Therapy Gene Therapy Targeting With Replicating Vector -Matthew Spear Chief Development Officer / Chief Medical Officer, Denovo Biopharma Precision Medicine/ Companion Diagnostics Trends Challenges Controversies And Cost Considerations Of Precision Oncology Approaches And Targeted Therapies -Karin Zeh Vice President, Program and Portfolio Management, Bristol Myers Squibb Biomarker Discovery Applications Of Biomarkers To Enhance Response To Immuno-oncology Therapeutics -Hui Zhou Chief Scientific Officer, Phanes Therapeutics, Inc. Clinical Research & Development Challenges And Opportunities In Oncology Clinical Development -Joanne Sloan Lancaster Vice President, Program Team Leadership, NGM Bio Investment, Private Equity & Venture Capital Partnerships An Insight Into The Investor Mindset How To Identify Analyse And Mitigate Risk In A Competitive Market -Stan Jin Co-founder and Chief Executive Officer, Molecular Axiom –(Co-facilitating) Jack Florio Managing Director, Weild & Co

Become an official strategy meeting partner. Whatever your business needs, we can help. Get in touch for partnering opportunities.

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D San Diego

Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024

Oncology

Strategy Meeting West Coast USA 2023

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hard Rock Hotel San Diego

Transforming the way we network

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Ana Krtolica

Anna Vardanyan

Oscar Segurado

Boris Minev

Charles Theuer

Gajanan Bhat

Gregory Opiteck

Jack Florio

Jason B. Litten

Joanne Sloan Lancaster

Joe Stalder

Karin Zeh

Majid Ghoddusi

Matthew Spear

Hui Zou

Nathaniel Wang

Ron Shazer

Stan Jin

Will Robberts

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

See Which Topics Are Up For Discussion

Opening Keynote

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Roundtable

Roundtable Tracks

Networking Lunch

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

PANEL DISCUSSION

Drinks Reception

Co-Host Sponsors

Key Opinion Leader

Press play to hear what your colleagues had to say…

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Hard Rock Hotel San Diego